A Retrospective Analysis to Evaluate the Effectiveness, Safety and Tolerability of Intravesical Valrubicin for the Treatment of Bladder Carcinoma in Situ in Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Valrubicin (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals
- 10 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 10 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.